At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immune Responses to Pneumococcal Vaccination Among HIV-Infected Subjects
In Brief
A clinical study evaluating (PV) 23-valent pneumococcal polysaccharide vaccine and Placebo for HIV Infections. Completed, enrolled 107 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment (ART). Participants in this study will be assigned by chance to receive vaccination with PV prior to starting ART or after at least 6 months of ART. Antibody levels to components of the PV will be measured at 6 months and 12 months after vaccination. The results will tell us if patients that receive PV after 6 months of ART have better response to the vaccine than those that get vaccinated prior to treatment.
Study Details
Timeline
Interventions
Currently commercially available pneumococcal polysaccharide vaccine
Placebo